Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growthAnthony M. Barsotti, Robert A. Rollins, Veronica Diesl et al.|Oncotarget|2015Cited by 46
Abstract 5144: Epigenetic reprogramming by tumor-derived EZH2 gain of function mutants leads to aggressive 3D-cell morphologies in both epithelial and melanoma cellsRobert A. Rollins, Dominique Verhelle, Anthony M. Barsotti et al.|Cancer Research|2014Cited by 0
Abstract 7182: EZH2 inhibition as a therapeutic strategy for castration resistant prostate cancer in combination with AR-antagonist enzalutamideShikhar Sharma, Pei‐Pei Kung, Jelena Petrovic et al.|Cancer Research|2025Cited by 0